Molecular Formula | C16H15N5 |
Molar Mass | 277.32 |
Density | 1.266±0.06 g/cm3(Predicted) |
Melting Point | 133-1350C |
Boling Point | 537.3±60.0 °C(Predicted) |
Flash Point | 278.765°C |
Solubility | Soluble in DMSO and Methanol. |
Vapor Presure | 0mmHg at 25°C |
Appearance | Bright yellow powder |
Color | Yellow to Dark Yellow |
pKa | 4.77±0.10(Predicted) |
Storage Condition | Keep in dark place,Inert atmosphere,2-8°C |
Refractive Index | 1.688 |
MDL | MFCD09028125 |
Use | Imatinib Intermediate |
HS Code | 29335990 |
imatinib | imatinib is the first generation tyrosine kinase inhibitor, a milestone drug in the history of treating chronic myeloid leukemia (CML), launched by Novartis in 2001, and is a successful model of targeted therapy. Only kill the BCR-ABL contained in myeloid cells, prevent cell proliferation and tumor formation, and have no effect on normal cells. It can also inhibit PDGF-mediated tumors, including glioma and prostate cancer. In the 1980s, scientific research showed that the granulocytes of most patients with chronic myeloid leukemia have two chromosomes transposed, resulting in a fusion kinase BCR-ABL, which led to the continuous activation of the kinase activity, resulting in uncontrolled cell proliferation-Blood cancer. On this basis, Dr. Druker, a biologist at Oregon University of Health Sciences in the United States, proposed the hypothesis of using BCR-ABL as a drug target and proposed the development of kinase inhibitors at this target to treat chronic myeloid leukemia. The second is the screening and optimization of the lead substance: then, Druker cooperated with Novartis chemist Nick Lydon to screen out small molecule inhibitors that inhibit BCR-ABL kinase from the compound library and optimized them to develop imatinib. Third, the results of preclinical studies and clinical trials show that imatinib is safe and effective. The vast majority of CML patients have achieved complete hematological remission, and the side effects are much less than cytotoxic anti-tumor drugs. |
Use | Imatinib intermediate |